{
    "clinical_study": {
        "@rank": "9908", 
        "arm_group": [
            {
                "arm_group_label": "CS+SG", 
                "arm_group_type": "Active Comparator", 
                "description": "Chondroitin sulfate + glucosamine sulfate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective is to assess the efficacy of a new formulation containing chondroitin\n      sulfate and glucosamine sulfate (CS+GS) compared with placebo in patients with primary\n      osteoarthritis of the knee."
        }, 
        "brief_title": "Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis", 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient >= 45 years .\n\n          -  Primary OA of the knee according to ACR criteria.\n\n          -  OA radiological grade II-III according to Kellgren and Lawrence.\n\n          -  Patients with moderate-severe pain.\n\n        Exclusion Criteria:\n\n          -  Patients with clinical significant trauma or surgery in the target knee.\n\n          -  Concurrent arthritic disease (antecedents and/or current signs) that could confound\n             or interfere with the evaluation of pain efficacy such as chondrocalcinosis, Paget's\n             disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic\n             osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis,\n             Wilson's disease, osteochondromatosis, seronegative spondyloarthropathy, mixed\n             connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel\n             disease or fibromyalgia.\n\n          -  Pain in other parts of the body greater than the knee pain that could interfere with\n             the evaluation.\n\n          -  Subjects with any active acute or chronic infections requiring antimicrobial therapy,\n             or serious viral (e.g., hepatitis, herpes zoster, HIV positivity) or fungal\n             infections.\n\n          -  Clinical diagnosis established of uncontrolled diabetes mellitus.\n\n          -  Patients with asthma.\n\n          -  History of hypersensitivity to the active drugs or any excipients of the\n             formulations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "314", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893905", 
            "org_study_id": "TM-CS+SG /301", 
            "secondary_id": "2013-000444-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "CS+SG", 
                "intervention_name": "Chondroitin sulfate + glucosamine sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "(multicentric Study)", 
                    "country": "Spain"
                }, 
                "name": "Several study sites"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee", 
        "overall_contact": {
            "email": "p.coronel@tedecmeiji.com", 
            "last_name": "Pilar Coronel, Ph. D.", 
            "phone": "+34 918870980"
        }, 
        "overall_official": {
            "affiliation": "Complejo Hospitalario Universitario La Coru\u00f1a", 
            "last_name": "FJ Blanco, Ph. D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reduction of pain using VAS", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893905"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "OMERACT-OARSI responder criteria", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "WOMAC Index (pain, stiffness and function)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Investigator global assessment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Patient global assessment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Consumption of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Adverse events recording", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Tedec-Meiji Farma, S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tedec-Meiji Farma, S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}